# Claudin 18.2

Source: https://onco.cc/targets/cldn18-2/  
OnCo record `cldn18-2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers.

## Summary

CLDN18.2 is normally buried in tight junctions of gastric mucosa; malignant transformation exposes it on the cell surface. Zolbetuximab (Vyloy) is approved with chemotherapy in CLDN18.2-positive gastric cancer. ADCs (CMG901/AZD0901, XNW27011), CAR-T (satricabtagene autoleucel, CT041), and bispecifics are in late-stage development.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target; car-t-target
- Symbol: CLDN18
- Class: surface-antigen
- Biology: Splice isoform 18.2; expressed in ~30-40% of gastric/GEJ adenocarcinomas and a subset of pancreatic ductal adenocarcinoma.
- Where found: Gastric/GEJ adenocarcinoma; Pancreatic ductal adenocarcinoma; Biliary

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CLDN18
- Wikipedia: https://en.wikipedia.org/wiki/CLDN18

## Connected records

- targets: [Claudin 6](https://onco.cc/targets/cldn6/)
- biomarkers: [Claudin 18.2 expression (>= 75% of tumour cells, moderate to strong)](https://onco.cc/biomarkers/cldn18-2-expression/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Claudin 18.2-positive gastric cancer](https://onco.cc/cancers/gastric-cldn18-2-positive/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [ASP2138](https://onco.cc/drugs/asp2138/), [AZD4360](https://onco.cc/drugs/azd4360/), [AZD5863](https://onco.cc/drugs/azd5863/), [BDC-4182](https://onco.cc/drugs/bdc-4182/), [IBI343](https://onco.cc/drugs/ibi343/), [LB4330](https://onco.cc/drugs/lb4330/), [LCB02A](https://onco.cc/drugs/lcb02a/), [LM-302](https://onco.cc/drugs/lm-302/), [M108](https://onco.cc/drugs/m108/), [RC118-ADC](https://onco.cc/drugs/rc118-adc/), [Satricabtagene autoleucel](https://onco.cc/drugs/satricabtagene-autoleucel/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/), [Spevatamig](https://onco.cc/drugs/spevatamig/), [TAC01-CLDN18.2](https://onco.cc/drugs/tac01-cldn18-2/), [XNW27011](https://onco.cc/drugs/xnw27011/), [Zolbetuximab](https://onco.cc/drugs/zolbetuximab/)
- companies: [Keymed Biosciences (KYM Biosciences)](https://onco.cc/companies/keymed/), [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/)
- pathways: [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/)
- trials: [CLARITY-Gastric 01](https://onco.cc/trials/clarity-gastric01/), [CT041-ST-01](https://onco.cc/trials/nct04581473/), [SPOTLIGHT & GLOW](https://onco.cc/trials/spotlight-glow/)
- pairings: [CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression](https://onco.cc/pairings/cldn18-antibody-then-adc/)
- ideas: [Biomarker-directed first-line quadruplets in gastric cancer](https://onco.cc/ideas/idea-biomarker-quadruplet-gastric/), [In vivo CAR-T against solid-tumour antigens](https://onco.cc/ideas/idea-in-vivo-car-solid/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- roadmaps: [Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR](https://onco.cc/roadmaps/cell-therapy-roadmap/)
- people: [Changsong Qi](https://onco.cc/people/qi-changsong/), [Jeeyun Lee](https://onco.cc/people/lee-jeeyun/), [Kohei Shitara](https://onco.cc/people/shitara-kohei/), [Lin Shen](https://onco.cc/people/shen-lin/), [Min-Hee Ryu](https://onco.cc/people/ryu-min-hee/), [Yoon-Koo Kang](https://onco.cc/people/kang-yoon-koo/), [Zev A. Wainberg](https://onco.cc/people/zev-wainberg/), [Zonghai Li](https://onco.cc/people/li-zonghai/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/)
- key papers: [Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial](https://onco.cc/key-papers/paper-ct041-st-01-lancet-2025/), [SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer](https://onco.cc/key-papers/paper-spotlight-lancet-2023/)
- institutions: [National Cancer Center Hospital East](https://onco.cc/institutions/ncc-hospital-east/), [Peking University Cancer Hospital](https://onco.cc/institutions/pku-cancer-hospital/)

---
JSON: https://onco.cc/api/v1/entities/cldn18-2.json